SG11202102405YA - 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) - Google Patents

1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)

Info

Publication number
SG11202102405YA
SG11202102405YA SG11202102405YA SG11202102405YA SG11202102405YA SG 11202102405Y A SG11202102405Y A SG 11202102405YA SG 11202102405Y A SG11202102405Y A SG 11202102405YA SG 11202102405Y A SG11202102405Y A SG 11202102405YA SG 11202102405Y A SG11202102405Y A SG 11202102405YA
Authority
SG
Singapore
Prior art keywords
ripk1
inhibitors
receptor
protein kinase
interacting protein
Prior art date
Application number
SG11202102405YA
Other languages
English (en)
Inventor
Junqing Guo
Jie Chen
Carolyn Diane Dzierba
Amy C Hart
Guanglin Luo
John E Macor
William J Pitts
Sing-Yuen Sit
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11202102405YA publication Critical patent/SG11202102405YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202102405YA 2018-09-13 2019-09-12 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) SG11202102405YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862730602P 2018-09-13 2018-09-13
PCT/US2019/050719 WO2020056072A1 (en) 2018-09-13 2019-09-12 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)

Publications (1)

Publication Number Publication Date
SG11202102405YA true SG11202102405YA (en) 2021-04-29

Family

ID=68073171

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102405YA SG11202102405YA (en) 2018-09-13 2019-09-12 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)

Country Status (14)

Country Link
US (1) US20220380335A1 (pt)
EP (1) EP3849968B1 (pt)
JP (1) JP2022500418A (pt)
KR (1) KR20210060517A (pt)
CN (1) CN112673000A (pt)
AU (1) AU2019337612A1 (pt)
BR (1) BR112021004385A2 (pt)
CA (1) CA3112735A1 (pt)
EA (1) EA202190718A1 (pt)
ES (1) ES2936481T3 (pt)
IL (1) IL281370A (pt)
MX (1) MX2021002509A (pt)
SG (1) SG11202102405YA (pt)
WO (1) WO2020056072A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3704118T3 (da) 2017-10-30 2022-03-14 Bristol Myers Squibb Co Aminoimidazopyrazin som kinasehæmmere
EA202091777A1 (ru) 2018-01-26 2020-10-14 Бристол-Маерс Сквибб Компани Аминопирролотриазины в качестве ингибиторов киназы
CA3153083A1 (en) * 2019-10-03 2021-04-08 Jie Chen Indazole carboxamides as kinase inhibitors
AR123793A1 (es) 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2424843B1 (en) * 2009-04-30 2014-03-26 Novartis AG Imidazole derivatives and their use as modulators of cyclin dependent kinases
KR20130077390A (ko) * 2011-12-29 2013-07-09 제이더블유중외제약 주식회사 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체
WO2014047024A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Iap antagonists
US9546153B2 (en) * 2012-11-08 2017-01-17 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
CA3112519A1 (en) * 2018-09-13 2020-03-19 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors

Also Published As

Publication number Publication date
BR112021004385A2 (pt) 2021-07-20
WO2020056072A1 (en) 2020-03-19
EA202190718A1 (ru) 2021-07-01
US20220380335A1 (en) 2022-12-01
JP2022500418A (ja) 2022-01-04
CN112673000A (zh) 2021-04-16
KR20210060517A (ko) 2021-05-26
ES2936481T3 (es) 2023-03-17
EP3849968A1 (en) 2021-07-21
MX2021002509A (es) 2021-04-28
IL281370A (en) 2021-04-29
CA3112735A1 (en) 2020-03-19
EP3849968B1 (en) 2022-12-21
AU2019337612A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
IL287136A (en) Receptor inhibitors - interacting with protein kinase 1
IL281370A (en) 1-Indazole Carboxamides as Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors
IL282179A (en) Protein tyrosine phosphatase inhibitors
IL283853A (en) Novel crispr-cas systems for genome editing
SI3397631T1 (sl) Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze
PL3317269T3 (pl) Laktamy bicykliczne jako inhibitory kinazy białka oddziałującego z receptorem-1 (rip1) do leczenia np. chorób zapalnych
IL281146A (en) Dimethyl amino aztidine amides as JAK inhibitors
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
IL281371A (en) Indazole carboxamides as kinase inhibitors
IL280719A (en) Transglutaminase 2 (tg2) inhibitors
EP3512539A4 (en) METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS
IL278255B1 (en) Inhibitor of mll1-wdr5 protein-protein interaction Phenyltriazole
ZA202000107B (en) Aminothiazole compounds as protein kinase inhibitors
EP3615937A4 (en) METHOD OF QUANTIFYING INTER-ALPHA INHIBITOR PROTEINS
EP4081283C0 (en) AEROSOL GENERATOR COMPRISING MULTIPLE POWER ELEMENTS
PL3735778T3 (pl) Współrzędne jako dane pomocnicze
GB201815670D0 (en) Protein editing
EP3568128A4 (en) HSP90B-N-TERMINALS ISOFORM SELECTIVE INHIBITORS
EP3258926A4 (en) Dimethoxyphenyl inhibitors of vesicular monoamine transporter 2
GB2589528B (en) Enabling software distribution
EP3687353B8 (en) High limit rtd holder block
GB201819391D0 (en) Media supply units
GB201807845D0 (en) Kinase Inhibitors
IL279215A (en) Mitogen-activated protein kinase kinase 7 inhibitors
EP3703540C0 (de) Verkaufstisch